Astellas acquires Iveric bio and with it avacincaptad pegol an important program for Geographic Atrophy,
Astellas Pharma Inc. and Iveric bio, Inc. announced that, the Companies have entered into a definitive agreement under which Astellas through Berry Merger Sub, Inc. a wholly-owned subsidiary of Astellas US Holding, Inc., has agreed to acquire 100% of the outstanding shares of Iveric Bio for US$40.00 per share in cash for a total equity value of approximately US$5.9 billion
In the acquisition, Iveric Bio will become an indirectly wholly-owned subsidiary of Astellas. Iveric Bio has promising programs including avacincaptad pegol an important program for Geographic Atrophy secondary to Age-Related Macular Degeneration.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins